Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Translational and Therapeutic Approaches to the Understanding and Treatment of Dyslipidemia.

× No keyword cloud information.

55 in total

1. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Authors: Brendan M Everett; Robert J Smith; William R Hiatt
Journal: N Engl J Med Date: 2015-10-07 Impact factor: 91.245

Review 2. Molecular biology of PCSK9: its role in LDL metabolism.

Authors: Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal: Trends Biochem Sci Date: 2007-01-09 Impact factor: 13.807

3. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.

Authors: Marianne Abifadel; Maryse Guerin; Suzanne Benjannet; Jean-Pierre Rabès; Wilfried Le Goff; Zélie Julia; Josée Hamelin; Valérie Carreau; Mathilde Varret; Eric Bruckert; Laurent Tosolini; Olivier Meilhac; Philippe Couvert; Dominique Bonnefont-Rousselot; John Chapman; Alain Carrié; Jean-Baptiste Michel; Annik Prat; Nabil G Seidah; Catherine Boileau
Journal: Atherosclerosis Date: 2012-05-17 Impact factor: 5.162

4. Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport.

Authors: Petra El Khoury; Elisa Waldmann; Thierry Huby; Julie Gall; Philippe Couvert; Jean-Marc Lacorte; John Chapman; Eric Frisdal; Philippe Lesnik; Klaus G Parhofer; Wilfried Le Goff; Maryse Guerin
Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-17 Impact factor: 8.311

Translational and Therapeutic Approaches to the Understanding and Treatment of Dyslipidemia.

1. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Review 2. Molecular biology of PCSK9: its role in LDL metabolism.

3. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.

4. Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport.

5. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

6. Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.

Review 7. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.

8. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo.

9. Emerging Roles of PCSK9: More Than a One-Trick Pony.

Review 10. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.

Review 1. Cardiovascular Immunotherapy and the Role of Imaging.